HHS Syndication Storefront

The HHS Syndication Storefront allows you to syndicate (import) content from many HHS websites directly into your own website or application. These services are provided by HHS free of charge.

Search Media Items

Filter results by:

Newest Syndicated Content

NCI

Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version

prevention  policy  treatment  cessation  patient  version  neoplasms  myeloproliferative  myelodysplastic  secondhand smoke  myelodysplastic/myeloproliferative neoplasms  Smoking Use and Tobacco Facts  Quitting Resources  Guidance, Regulations and Compliance  Prevent Smoking and Tobacco Use 

Myelodysplastic/myeloproliferative neoplasms treatment options include supportive care, chemotherapy, radiation therapy, surgery, biologic/targeted therapy, and stem cell transplant. Learn more about these diseases in this expert-reviewed summary.

Preview   0 Users liked this content.
NCI

Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version

prevention  research  treatment  chronic  disorders  cessation  patient  version  myeloproliferative  secondhand smoke  chronic myeloproliferative neoplasms  Smoking Use and Tobacco Facts  Quitting Resources  Guidance, Regulations and Compliance  Prevent Smoking and Tobacco Use 

Chronic myeloproliferative neoplasms treatments vary and depend upon the specific diagnosis. Treatment may include observation, phlebotomy, transfusions, chemotherapy/medications, radiation, biologic/targeted therapy, and stem cell transplant. Learn more in this expert-reviewed summary.

Preview   0 Users liked this content.
NCI

Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version

prevention  health  research  policy  treatment  cessation  version  professional  neoplasms  myeloproliferative  myelodysplastic  secondhand smoke  myelodysplastic/myeloproliferative neoplasms  Smoking Use and Tobacco Facts  Quitting Resources  Guidance, Regulations and Compliance  Prevent Smoking and Tobacco Use 

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are treated with chemotherapy or other drugs, stem cell transplant, supportive care, and targeted therapy. They include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). Learn about the clinical features and treatment options for these leukemias.

Preview   0 Users liked this content.
NCI

Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version

prevention  health  research  policy  treatment  chronic  cessation  version  professional  neoplasms  myeloproliferative  secondhand smoke  chronic myeloproliferative neoplasms  Smoking Use and Tobacco Facts  Quitting Resources  Guidance, Regulations and Compliance  Prevent Smoking and Tobacco Use 

Chronic Myeloproliferative Neoplasms (MPN) treatment varies widely depending on the specific diagnosis. Treatment options may include observation, phlebotomy, steroids, chemotherapy, immunotherapy, and stem cell transplant. Get detailed information about MPNs in this summary for clinicians.

Preview   0 Users liked this content.

What is Content Syndication?

Want to place content from HHS websites onto your own site? Syndication allows you to offer high-quality HHS content in the look and feel of your site, without the need to manually update it.

Learn more >>

Syndication API

With the HHS Syndication API, you can retrieve HHS's vast repository of public health content.

decorativeGearLogoIcon

An API, or Application Programming Interface, is a way for two computer applications to talk to each other in a common language that they both understand. HHS's API provides a structured way to get HHS content in a predictable, flexible and powerful format.

API Documentation >>

Additional Information

Connect With Us

Share on facebook Visit the HHS Twitter account Share on youtube

Share on flickr Share on pinterest Visit HHS GooglePlus account

U.S. Department of Health & Human Services - 200 Independence Avenue, S.W. - Washington, D.C. 20201